Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $11.8452W HIGH $19.70
Volume
25.13 K
Value Traded
1.11 M
Short % Float
19.18%
Days to Cover
28.2
-5.51%Week
-13.85%1 Month
-16.96%3 Month
-27.58%6 Month
-35.09%5 Year
-85.19%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
155.13 M
EPS (TTM)
-2.10
P/E Ratio
-
Ent. Value
168.62 M
Total Shares
12.85 M
Float Shares
9.62 M
Insiders
25.52%
Institutions
53.87%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
MDWD Catalyst Timeline
Dated clinical, regulatory and corporate events for MediWound Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for MediWound Ltd.
693Total events
9Upcoming
190Tier-1 (high impact)
2013 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Grant / FundingNexoBridApprovedCorporate
DoW awards additional $3.3 million for room-temperature-stable NexoBrid formulation, raising total program budget to $21.8 million
battlefield burn caresource ↗
▲DSMB ReviewEscharExTrial
Independent DSMB completes pre-specified periodic safety review of Phase III VALUE study; no safety concerns, recommends continuation without modification
venous leg ulcers (VLU)source ↗
▲Partnership / LicenseNexoBridApprovedCorporate
Master Services Agreement signed with Vericel under its BARDA contract
▲Partnership / LicenseEscharExCorporate
Medline joined EscharEx clinical development program through research collaboration agreement
venous leg ulcerssource ↗
▲PublicationEscharExPresentation
Peer-reviewed U.S. expert consensus document published in WOUNDS
chronic wound caresource ↗
▲Partnership / LicenseNexoBridApprovedCorporate
Vericel awarded ten-year BARDA contract valued up to $197 million for NexoBrid
burn caresource ↗
▲PublicationNexoBridApprovedPresentation
NEXT Expanded Access Program published in Journal of Burn Care & Research
burnsource ↗
▲Equity OfferingCorporate
Received $0.7 million from exercise of Series A warrants after quarter-end
◆Poster PresentationEscharExPresentation
Post-hoc analysis at EWMA 2026 on efficacy of bromelain-based debridement in DFUs
diabetic foot ulcerssource ↗
◆Oral PresentationEscharExPresentation
Scientific session at SAWC Spring 2026 on bromelain-based therapy from burns to chronic wounds, including VALUE trial updates
chronic woundssource ↗
◆Poster PresentationEscharExPresentation
Post-hoc analysis from ChronEx Phase II at SAWC Spring 2026 on wound bed preparation and co-primary endpoint
venous leg ulcerssource ↗
▲Partnership / LicenseNexoBridApprovedCorporate
BARDA contract awarded to Vericel for NexoBrid procurement and development
thermal burnssource ↗
◆Trial InitiationEscharExTrial
Initiation of investigator-initiated trial of EscharEx in PUs planned in mid-2026
pressure ulcerssource ↗
◆Interim AnalysisEscharExTrial
Interim sample size assessment after 65% of patients complete treatments in VALUE trial
venous leg ulcerssource ↗
◆Quarterly UpdateCorporate
Q4 and Full Year 2025 Financial Results Release and Conference Call
◆Partnership / LicenseNexoBridApprovedCorporate
Potential multi-year program with BARDA expected to progress toward completion in Q1 2026
▲Oral PresentationEscharExPresentation
New clinical and preclinical data presented at 2026 WHS, SAWC Spring, and EWMA conferences
chronic woundssource ↗
▲Manufacturing MilestoneNexoBridApprovedCMC / Inspection
Expanded GMP manufacturing facility expected to achieve full operational readiness
deep partial- and full-thickness thermal burnssource ↗
◆Trial InitiationEscharExTrial
Preparations for DFU Phase 2/3 study progressing as planned
diabetic foot ulcerssource ↗
◆Manufacturing MilestoneCMC / Inspection
New manufacturing facility expected to reach full operational capacity by end of 2025
▲PublicationNexoBridApprovedPresentation
Publication of prospective clinical data on NexoBrid for preventing traumatic tattoos
traumatic tattoos after abrasion and blast injuriessource ↗
▲Manufacturing MilestoneNexoBridApprovedCMC / Inspection
New manufacturing facility commissioning on schedule; full operational capacity by year-end 2025
◆Enrollment UpdateEscharExTrial
Ongoing enrollment continues in VALUE Phase III trial of EscharEx in venous leg ulcers
venous leg ulcerssource ↗
▲Manufacturing MilestoneNexoBridApprovedCMC / Inspection
Commissioning completed for expanded NexoBrid facility
▲Manufacturing MilestoneNexoBridApprovedCMC / Inspection
Successfully completed commissioning of expanded GMP manufacturing facility for NexoBrid
deep partial- and full-thickness thermal burnssource ↗
▲Product LaunchNexoBridApprovedPost-Market
Commercial launch in Australia expected in Q4 2025 by partner Balance Medical
deep partial- and full-thickness thermal burnssource ↗
▼Equity OfferingCorporate
Announced $30 million registered direct offering of ordinary shares
▲Other Regulator MilestoneNexoBridApprovedEx-US Regulatory
TGA grants marketing authorization for NexoBrid in Australia for adults and children
deep partial- and full-thickness thermal burnssource ↗
◆Oral PresentationPresentation
CEO Ofer Gonen to present at H.C. Wainwright 27th Annual Global Investment Conference
◆Oral PresentationNexoBridApprovedPresentation
36 scientific presentations at 21st EBA Congress
burn debridementsource ↗
◆Enrollment UpdateEscharExTrial
VALUE Phase III trial of EscharEx in venous leg ulcers continues to enroll patients
venous leg ulcerssource ↗
▲Partnership / LicenseEscharExCorporate
Additional strategic research collaborations established with Essity and Convatec for EscharEx
▲Full ResultsEscharExClinical Data
Publication of post hoc analysis of ChronEx trial in Advances in Wound Care showing correlation between wound bed preparation and wound closure
venous leg ulcerssource ↗
◆Trial InitiationEscharExTrial
Global Phase III study in venous leg ulcers currently underway
venous leg ulcerssource ↗
◆Enrollment MilestoneEscharExTrial
Majority of European sites expected to be activated
venous leg ulcerssource ↗
◆Trial InitiationEscharExTrial
Initiation of Phase II/III study for Diabetic Foot Ulcers
Diabetic Foot Ulcerssource ↗
◆Enrollment UpdateEscharExTrial
Recruitment underway in VALUE Phase III trial for VLUs
venous leg ulcerssource ↗
◆Oral PresentationEscharExPresentation
Oral presentation at WHS and SAWC Spring 2025 conferences
chronic woundssource ↗
Past FDA Catalysts and PDUFA Decisions
How MDWD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-06 | EscharEx (ChronEx Phase II) | Phase 2 data presentation | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 59%
Micro Cap(rank 388 of 657)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (20-F and 6-K), to Jun 2026; product lines: last four quarters to Jun 2026 (20-F and 6-K))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| NexoBrid |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EscharEx Small moleculeNCT06690177 | Venus Leg Ulcers | Phase 2 | NOT YET_RECRUITING | 45 | Jan 16, 2029 | ||||||
| EscharEx Small moleculeNCT05157763 | Superficial Basal Cell Carcinoma | Phase 1 | RECRUITING | 32 | Jun 1, 2022 | ||||||
| EscharEx Small moleculeNCT03588130 | Venous Leg Ulcer | Phase 3 | COMPLETED | 368 | Mar 23, 2022 | ||||||
| EscharEx Small moleculeMarketedNCT02020746 | Hard to Heal Wounds | Phase 2 | COMPLETED | 111 | Jun 4, 2018 | ||||||
| NexoBrid Small moleculeMarketedNCT02148705 | Thermal Burns | Phase 3 | COMPLETED | 320 | Aug 20, 2020 |
Clinical Trial Results
Readouts, endpoints and source filings for every MDWD program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Rubinstein SamuelDirector | Sell | -525 | $12.72 | 09/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MDWD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| DAFNA Capital Management LLC | 0.3 % | 1.39 M | 94.41 K |
MDWD Institutional Ownership Trends
MDWD Short Interest
Shares sold short, counted twice a month.
19.18%
Short % of Float
of tradable shares sold short
1.8M
Shares Sold Short
+1.7% vs prior count
28.2 Very high
Days to Cover
trading days of normal volume to buy every short share back
65.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MDWD ranks across every disease it competes in
Competitive Position is a premium feature
See how MDWD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMDWD News
MDWDMediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
MediWound Ltd. has been awarded an additional $3.3 million by the U.S. Department of War to further develop a room-temperature-stable formulation of NexoBrid. This funding increases the total program budget to $21.8 million and aims to support the Investigational New Drug submission for battlefield burn care. The new formulation is designed to enhance storage and handling in austere settings.
Read more →MDWD▲ +5.9%on this news
Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification
MediWound Ltd. announced that the independent Data and Safety Monitoring Board (DSMB) has recommended the continuation of the Phase III VALUE study for EscharEx without any modifications. The DSMB found no safety concerns during its review, and the study remains on track for interim reassessment and completion of patient enrollment by the end of Q1 2027. This recommendation supports the favorable safety profile of EscharEx observed in previous studies.
Read more →MDWDMediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
MediWound Ltd. announced that CEO Ofer Gonen will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The event is scheduled for September 14-16, 2026, in New York City. A live webcast will be available for those unable to attend in person.
Read more →MDWDMediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
MediWound Ltd. reported its second quarter 2026 financial results, highlighting progress in its EscharEx Phase III VALUE trial and a new agreement with Vericel for NexoBrid. The company reaffirmed its revenue guidance for the year, despite a decrease in second quarter revenue and an increase in operating losses. The interim assessment for the VALUE trial is expected by the end of Q1 2027.
Read more →MDWDMediWound to Report Second Quarter 2026 Financial Results
MediWound Ltd. will announce its financial results for the second quarter of 2026 on August 13, 2026. A conference call and webcast will follow at 8:30 a.m. ET to discuss these results and provide a corporate update. The company is known for its innovative enzymatic therapies, including the FDA-approved NexoBrid and the investigational EscharEx.
Read more →MDWD▼ -14.1%on this news
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
MediWound Ltd. reported its first quarter 2026 financial results, highlighting ongoing progress in the Phase III VALUE trial for EscharEx and reaffirming its revenue guidance of $24-26 million for the year. Despite a revenue decline to $1.5 million, the company noted strong engagement from collaborators and expanding adoption of NexoBrid in the U.S. burn care market. The company is focused on enhancing recruitment for clinical trials and addressing regulatory requirements for manufacturing.
Read more →MDWDMediWound to Report First Quarter 2026 Financial Results
MediWound Ltd. will announce its financial results for the first quarter of 2026 on May 27th. The management will conduct a conference call and webcast at 8:30 a.m. ET to discuss these results and provide a company update. MediWound is known for its enzymatic therapies for tissue repair, including its FDA-approved product NexoBrid® and investigational therapy EscharEx®.
Read more →MDWDNewly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement
MediWound Ltd. announced the publication of a peer-reviewed consensus that redefines chronic wound debridement as a biologically active intervention. The consensus emphasizes the importance of early, less invasive treatments and supports the use of EscharEx® as a promising option for effective wound care. This aligns with MediWound's strategy to enhance chronic wound management.
Read more →MDWDMediWound to Present New EscharEx Data at Leading Wound Care Conferences
MediWound Ltd. announced that it will present new data on its EscharEx therapy at leading wound care conferences, highlighting its mechanism of action and clinical advantages. The presentations will include positive findings from a Phase III study focused on venous leg ulcers and plans for expansion into diabetic foot ulcers and pressure ulcers. New data has shown EscharEx's superiority in debridement compared to SANTYL, while supporting current and future clinical trials. The therapy is noted for its efficacy in promoting wound healing across various studies.
Read more →MDWDMediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
MediWound Ltd. announced that Vericel Corporation has been awarded a ten-year contract by BARDA worth up to $197 million for NexoBrid. The contract includes procurement, a Vendor Managed Inventory system, and development of a new formulation. The base period of the contract is valued at $35 million, with additional optional awards for expanded procurement and clinical development.
Read more →MDWDMediWound Reports Fourth Quarter and Full Year 2025 Financial Results
MediWound Ltd. reported its financial results for Q4 and full year 2025, highlighting the progress of its Phase III VALUE trial for EscharEx and the operational status of its expanded NexoBrid manufacturing facility. Despite a decrease in revenue and an increase in operating loss, the company maintains a strong cash position and has reaffirmed its revenue guidance for the upcoming years. Key milestones are anticipated in the clinical development of EscharEx.
Read more →MDWDMediWound Files Annual Report on Form 20-F
MediWound Ltd. has filed its annual report on Form 20-F for the fiscal year ending December 31, 2025, with the U.S. SEC. The report is accessible online, and hard copies are available free to shareholders upon request. The company focuses on enzymatic therapies for tissue repair, with products like NexoBrid approved for use in various international markets and the investigational therapy EscharEx in late-stage development.
Read more →MDWDMediWound to Report Fourth Quarter and Full Year 2025 Financial Results
MediWound Ltd. has announced the upcoming release of its financial results for the fourth quarter and full year ended December 31, 2025. The report will be disclosed on March 5, 2026, followed by a conference call and live webcast hosted by the management team to discuss the highlights. MediWound is known for its pioneering enzymatic therapies, including its FDA-approved product, NexoBrid, and its investigational product, EscharEx.
Read more →MDWDMediWound to Present at Upcoming Investor Conferences
MediWound Ltd. will present at two upcoming investor conferences, the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the TDCowen 46th Annual Health Care Conference. The presentations will showcase the company's advancements in enzymatic therapeutics for tissue repair, including their FDA-approved product NexoBrid and the investigational therapy EscharEx. Webcasts of the presentations will be available for interested parties.
Read more →MDWD▼ -7.9%on this news
MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference
MediWound Ltd. provided a corporate and financial update ahead of the J.P. Morgan Healthcare Conference, highlighting their progress in clinical trials and manufacturing capabilities. The company anticipates completing enrollment for its EscharEx VALUE trial in venous leg ulcers by year-end 2026 and plans to expand the product to diabetic foot ulcers and pressure ulcers in the same year. Additionally, MediWound reported updated revenue guidance projecting significant growth in the coming years, backed by a strong cash position and operational enhancements.
Read more →MDWDMediWound Reports New Clinical Data Demonstrating NexoBrid ’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries
MediWound Ltd. has announced positive clinical data demonstrating the effectiveness of NexoBrid in preventing traumatic tattoos caused by abrasion and blast injuries. The peer-reviewed study indicated that NexoBrid achieved over a 90% reduction in pigmented wound areas. Conducted at the Sheba Medical Center, the study included 15 patients who were treated with NexoBrid within 24 hours of their injuries, showing promising results in particle removal while being well-tolerated. Despite the favorable outcomes, the study's small sample size and short follow-up period suggest the need for further investigation to confirm long-term effects.
Read more →MDWD▼ -5.6%on this news
MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update
MediWound reported third quarter 2025 revenue of $5.4 million, a 23 percent increase from the prior year. The company raised $30 million through equity financing to strengthen its balance sheet. Operating loss widened to $6.5 million as research and development expenses rose. Net loss decreased to $2.7 million due to non-cash financial income from warrant revaluation.
Read more →MDWDMediWound to Report Third Quarter 2025 Financial Results
MediWound Ltd. will announce its financial results for the third quarter of 2025 on November 20, 2025. Following the announcement, management will host a conference call and webcast to discuss the results and provide a corporate update. The company is known for its enzymatic therapies, including the FDA-approved NexoBrid and the investigational EscharEx.
Read more →MDWDMediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®
MediWound Ltd. has successfully completed the commissioning of its expanded GMP manufacturing facility in Yavne, Israel, which will increase production capacity for NexoBrid by sixfold. The facility is expected to be fully operational by the end of 2025, enabling the company to meet growing global demand for its product. This achievement reflects MediWound's commitment to operational excellence and timely access for patients across more than 40 approved markets.
Read more →MDWDMediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
MediWound Ltd. has announced a $30 million registered direct offering of ordinary shares, led by a U.S.-based mutual fund. The offering involves 1,734,105 shares priced at $17.30 each, expected to close by September 30, 2025. Proceeds will primarily support pre-commercial activities for EscharEx and enhance manufacturing capabilities.
Read more →About MediWound Ltd.
BIOPHARMAWATCH ELITE PLUS
Trade the next MDWD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime